Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with AML (a type of blood cancer) that has a specific gene change called a CEBPA mutation, confirmed by molecular testing.
• People whose AML has certain high-risk features, such as a protein called CD7 on their cancer cells, a WT1 gene mutation, a specific type of CEBPA mutation, a complex chromosome pattern, or detectable traces of leukemia remaining after two rounds of chemotherapy (measured by specialised lab tests).
• People whose diagnosis has been confirmed through detailed testing (covering cell type, chromosome, molecular, and immune markers), and where other related blood conditions such as MDS or treatment-related AML have been ruled out.
• People aged 18 to 64 years old.
• People whose liver and kidney function fall within acceptable ranges (specific blood test values within defined limits).
• People with normal heart function, confirmed by an echocardiogram showing the heart pumping at least 50% efficiency, and classified as Class I or II under standard heart function guidelines.
• People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (ECOG score), meaning they are reasonably active and able to care for themselves.
• People whose white blood cell count was below a certain level at diagnosis and who have not received any chemotherapy other than a drug called hydroxyurea before starting treatment in this trial.
• People whose white blood cell count was at or above a certain level at diagnosis, for whom limited prior treatment with cytarabine or hydroxyurea before starting the trial is allowed.
• Women who are not currently pregnant or breastfeeding.
• Women who could potentially become pregnant must have a negative pregnancy blood test (hCG) before joining.
• People (or their family member, where applicable) who have signed an informed consent form agreeing to take part.

Who may not be able to join:

• People whose AML developed from another blood condition called MDS, or whose AML was caused by prior cancer treatment, or who have a mixed-cell type of leukemia, or who have leukemia that has spread to the brain or to areas outside the bone marrow.
• People whose AML has already relapsed (come back after treatment).
• People who are known to be allergic to, or who have medical reasons to avoid, any of the drugs used in this trial.
• People whose liver or kidney function test results fall outside the acceptable ranges set for this trial.
• People with significant heart problems, including a heart pumping rate below 50%, heart failure rated Class III or IV, fluid around the heart above a certain severity level, a heart attack in the past six months, or an abnormal heart rhythm reading on an ECG.
• People with significant lung problems, including fluid on or around the lungs above a certain severity level.
• People who currently have another type of cancer in another organ.
• People with an active infection from Hepatitis A, B, or C, active tuberculosis, or who test positive for HIV.
• People who have another blood disorder alongside their leukemia, including abnormal blood clotting that is unrelated to the leukemia.
• People who are unable to understand or follow the study's instructions and requirements.
• People who are currently participating in another clinical trial, or who have any other condition that would prevent safe participation in this study.

Important: Always verify eligibility with the trial site directly before applying.